BR0011178A - Molécula sintética biologicamente ativa, método para sua preparação e medicamento baseado na mesma - Google Patents
Molécula sintética biologicamente ativa, método para sua preparação e medicamento baseado na mesmaInfo
- Publication number
- BR0011178A BR0011178A BR0011178-3A BR0011178A BR0011178A BR 0011178 A BR0011178 A BR 0011178A BR 0011178 A BR0011178 A BR 0011178A BR 0011178 A BR0011178 A BR 0011178A
- Authority
- BR
- Brazil
- Prior art keywords
- biologically active
- synthetic molecule
- preparation
- same
- active synthetic
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 101000714457 Chaetoceros protobacilladnavirus 2 Capsid protein Proteins 0.000 abstract 2
- 241001505332 Polyomavirus sp. Species 0.000 abstract 2
- 101710108545 Viral protein 1 Proteins 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Polyamides (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
"MOLéCULA SINTéTICA BIOLOGICAMENTE ATIVA, MéTODO PARA SUA PREPARAçãO E MEDICAMENTO BASEADO NA MESMA". A presente invenção está relacionada a uma molécula sintética biologicamente ativa para a fixação de um ingrediente ativo à proteína viral 1 ( VP1 ) do vírus polyoma. De acordo com a presente invenção, a seq³ência de aminoácidos A1 que é derivada da extremidade C-terminal da proteína viral 2 ( VP2 ) ou 3 ( VP3 ) do vírus polyoma é ligada a um ingrediente ativo em uma de suas extremidades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19916224A DE19916224C1 (de) | 1999-04-10 | 1999-04-10 | Synthetisches biologisch aktives Molekül |
PCT/DE2000/000976 WO2000061616A1 (de) | 1999-04-10 | 2000-04-03 | Fragmente des virus proteins 2 oder 3 des polymavirus als fähren für wirkstoffe |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0011178A true BR0011178A (pt) | 2002-05-21 |
Family
ID=7904139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0011178-3A BR0011178A (pt) | 1999-04-10 | 2000-04-03 | Molécula sintética biologicamente ativa, método para sua preparação e medicamento baseado na mesma |
Country Status (19)
Country | Link |
---|---|
US (2) | US7011968B1 (pt) |
EP (2) | EP1173475B1 (pt) |
JP (1) | JP2002544122A (pt) |
KR (1) | KR100627935B1 (pt) |
CN (1) | CN1346366A (pt) |
AT (1) | ATE303401T1 (pt) |
AU (1) | AU768669B2 (pt) |
BR (1) | BR0011178A (pt) |
CA (1) | CA2364536A1 (pt) |
CZ (1) | CZ20013621A3 (pt) |
DE (3) | DE19916224C1 (pt) |
EA (1) | EA006631B1 (pt) |
HU (1) | HUP0200679A2 (pt) |
IL (1) | IL145403A0 (pt) |
MX (1) | MXPA01010189A (pt) |
NO (1) | NO20014891L (pt) |
PL (1) | PL355852A1 (pt) |
WO (1) | WO2000061616A1 (pt) |
ZA (1) | ZA200107658B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19916224C1 (de) * | 1999-04-10 | 2000-06-21 | November Ag Molekulare Medizin | Synthetisches biologisch aktives Molekül |
GB2357084A (en) * | 1999-12-06 | 2001-06-13 | Amersham Pharm Biotech Uk Ltd | A hydrophobic carrier peptide |
DE10306789A1 (de) * | 2003-02-18 | 2004-08-26 | Responsif Gmbh | Zusammensetzung zur Verabreichung an ein Lebewesen und Verfahren zur Markierung von Mitteln |
US20090062237A1 (en) * | 2007-06-15 | 2009-03-05 | Mayo Foundation For Medical Education And Research | Evaluating immune competence |
EP2636746A1 (en) * | 2012-03-06 | 2013-09-11 | Life Science Inkubator | A novel drug delivery system based on JCV-VLP |
CN113278634B (zh) * | 2020-11-16 | 2022-06-28 | 艾棣维欣(苏州)生物制药有限公司 | 一种预防和治疗默克尔细胞癌的新型疫苗 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1319101C (en) | 1986-09-03 | 1993-06-15 | Marta Iris Sabara | Rotavirus nucleocapsid protein with or without binding peptides as immunologic carriers for macromolecules |
US4950599A (en) * | 1987-01-29 | 1990-08-21 | Wolf Bertling | Method for exchanging homologous DNA sequences in a cell using polyoma encapsulated DNA fragments |
GB9114003D0 (en) | 1991-06-28 | 1991-08-14 | Mastico Robert A | Chimaeric protein |
DE656950T1 (de) * | 1992-08-21 | 1996-03-14 | Biogen Inc | Tat-derivate transport polypeptide. |
US5618536A (en) * | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
DE4335025A1 (de) | 1993-10-14 | 1995-04-20 | Boehringer Ingelheim Int | Endosomolytisch wirksame Partikel |
DE19543553B4 (de) * | 1995-11-22 | 2009-04-09 | Deutsches Primatenzentrum Gmbh | VP-Antigene des JC-Virus |
DE19618797C2 (de) * | 1996-05-10 | 2000-03-23 | Bertling Wolf | Vehikel zum Transport molekularer Substanz |
US5858648A (en) * | 1996-11-04 | 1999-01-12 | Sienna Biotech, Inc. | Assays using reference microparticles |
DE19916224C1 (de) * | 1999-04-10 | 2000-06-21 | November Ag Molekulare Medizin | Synthetisches biologisch aktives Molekül |
-
1999
- 1999-04-10 DE DE19916224A patent/DE19916224C1/de not_active Expired - Fee Related
-
2000
- 2000-04-03 BR BR0011178-3A patent/BR0011178A/pt not_active Application Discontinuation
- 2000-04-03 DE DE10080849T patent/DE10080849D2/de not_active Expired - Fee Related
- 2000-04-03 EP EP00922458A patent/EP1173475B1/de not_active Expired - Lifetime
- 2000-04-03 AT AT00922458T patent/ATE303401T1/de not_active IP Right Cessation
- 2000-04-03 HU HU0200679A patent/HUP0200679A2/hu unknown
- 2000-04-03 DE DE50011068T patent/DE50011068D1/de not_active Expired - Fee Related
- 2000-04-03 EP EP05009073A patent/EP1586582A1/de not_active Withdrawn
- 2000-04-03 AU AU42850/00A patent/AU768669B2/en not_active Ceased
- 2000-04-03 EA EA200101066A patent/EA006631B1/ru not_active IP Right Cessation
- 2000-04-03 CA CA002364536A patent/CA2364536A1/en not_active Abandoned
- 2000-04-03 WO PCT/DE2000/000976 patent/WO2000061616A1/de active IP Right Grant
- 2000-04-03 PL PL00355852A patent/PL355852A1/xx not_active Application Discontinuation
- 2000-04-03 CZ CZ20013621A patent/CZ20013621A3/cs unknown
- 2000-04-03 IL IL14540300A patent/IL145403A0/xx unknown
- 2000-04-03 US US09/958,451 patent/US7011968B1/en not_active Expired - Fee Related
- 2000-04-03 JP JP2000611557A patent/JP2002544122A/ja active Pending
- 2000-04-03 KR KR1020017012890A patent/KR100627935B1/ko not_active IP Right Cessation
- 2000-04-03 MX MXPA01010189A patent/MXPA01010189A/es unknown
- 2000-04-03 CN CN00806109A patent/CN1346366A/zh active Pending
-
2001
- 2001-09-18 ZA ZA200107658A patent/ZA200107658B/en unknown
- 2001-10-08 NO NO20014891A patent/NO20014891L/no not_active Application Discontinuation
-
2005
- 2005-12-22 US US11/316,467 patent/US20070009921A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE303401T1 (de) | 2005-09-15 |
JP2002544122A (ja) | 2002-12-24 |
KR100627935B1 (ko) | 2006-09-22 |
PL355852A1 (en) | 2004-05-31 |
MXPA01010189A (es) | 2003-07-21 |
EP1173475A1 (de) | 2002-01-23 |
NO20014891L (no) | 2001-11-07 |
US7011968B1 (en) | 2006-03-14 |
EA200101066A1 (ru) | 2002-04-25 |
KR20020007361A (ko) | 2002-01-26 |
CA2364536A1 (en) | 2000-10-19 |
HUP0200679A2 (en) | 2002-06-29 |
ZA200107658B (en) | 2002-07-22 |
EP1586582A1 (de) | 2005-10-19 |
EA006631B1 (ru) | 2006-02-24 |
CN1346366A (zh) | 2002-04-24 |
DE19916224C1 (de) | 2000-06-21 |
IL145403A0 (en) | 2002-06-30 |
EP1173475B1 (de) | 2005-08-31 |
DE50011068D1 (de) | 2005-10-06 |
US20070009921A1 (en) | 2007-01-11 |
DE10080849D2 (de) | 2002-06-27 |
CZ20013621A3 (cs) | 2002-05-15 |
WO2000061616A1 (de) | 2000-10-19 |
AU4285000A (en) | 2000-11-14 |
NO20014891D0 (no) | 2001-10-08 |
AU768669B2 (en) | 2003-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9608449A (pt) | Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica. | |
BR0111366A (pt) | Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv) | |
EA200200106A1 (ru) | Фармацевтическая композиция леводопа/карбидопа/энтакапон | |
DE69428040D1 (de) | Orale darreichungsform | |
BR9812068A (pt) | Processo para a cicatrização óssea e restauração de fraturas e utilização de um análogo de polipeptìdeo de peptìdeo (pthrp) relacionado com hormÈnios de paratireóide e seus sais | |
CA2181150A1 (en) | Biologically Active Peptides from Functional Domains of Bactericidal/Permeability-Increasing Protein and Uses Thereof | |
HK1014191A1 (en) | Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof | |
DK0692970T3 (da) | Anvendelse af actin-bindende forbindelser til fremstilling af et lægemiddel til reduktion af viskositeten af patologisk sli | |
BR9508467A (pt) | Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal | |
BR9712202A (pt) | Composto, processo para preparar o mesmo, composicão farmacêutica, processo para o tratamento de inflamacão neurogênica em um indivíduo em necessidade deste tratamento, e, uso do composto. | |
BR9914631A (pt) | Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades | |
BR0012919A (pt) | Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv | |
BR0011178A (pt) | Molécula sintética biologicamente ativa, método para sua preparação e medicamento baseado na mesma | |
DE69531004D1 (de) | p277 PEPTIDANALOGE, PHARMAZEUTISCHE ZUSAMMENSTELLUNG DAVON ZUR BEHANDLUNG UND DIAGNOSE VON DIABETES | |
PT1079849E (pt) | Utilizacao de proteinas hmg para a preparacao de medicamentos com actividade citotoxica | |
BR9607628A (pt) | Mólecula proteinácea biologicamente isolada, molécula recombinante, fragmento de peptìdeo, molécula de ácido nucleico, composição farmacêutica, e, processos para preparar uma molécula recombinante e para induzir a proliferação astroglial em um mamìfero | |
BR0112515A (pt) | Complexo protéico utilizado como veìculo para medicamentos oralmente administráveis | |
DE69322872D1 (de) | Vakzine gegen immunodefizienz-virus der katze (kiv) | |
KR910002899A (ko) | 혈조절 펩타이드 | |
BR9809103A (pt) | Forma farmacêutica estável de administração para peptìdeos, proteìnas e ácidos nucléicos | |
BR9106676A (pt) | Peptideo,processo para promover a liberacao de niveis de hormonio de crescimento em um animal,composicao farmaceutica para promover a liberacao de niveis de hormonio de crescimento em animais,uso do composto e processo para promover a liberacao e elevacao de niveis de hormonio de crescimento no sangue | |
DE69430295D1 (de) | Pulver zur nasalen Verabreichung peptidischer oder proteinischer Arzneistoffe | |
BR9712306A (pt) | Processo para preparação de um preparado de igm para aplicação endovenosa | |
BR0112381A (pt) | Componente farmacêutico com base em hormÈnio da paratireóide humana e uma composição farmacêutica para administração intranasal compreendendo o componente | |
DE69630682D1 (de) | Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: C07K 14/005 (2006.01), A61K 47/62 (2017.01), A61K |